ClinicalTrials.gg
Enrolling by invitationNCT03054792Updated Apr 29, 2026

Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas

A Phase 1 interventional study of Blood Oxygen Level Dependent [BOLD] MRI and Diffusion-Weighted [DW] MRI in Rhabdomyosarcoma and Non-Rhabdo. Soft Tissue Sarcoma, sponsored by The Hospital for Sick Children. Enrolling by invitation at 1 site in Canada. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by The Hospital for Sick Children · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
6 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Rhabdomyosarcoma with a site in Canada — 4 open to participants now, 9 under way, 3 of them phase 3. Rhabdomyosarcoma · Canada.

Planned enrollment
27th of 30
18 · median 106
Started
2017
with 2 others
Phase 1
3 of 32
1 open now
Registered
23rd of 32
by date

Among the 32 studies in Rhabdomyosarcoma with a site in Canada, this one is the 27th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2017, is one of 3 in phase 1, and was the 23rd registered.

Rhabdomyosarcoma

238 studies on the registry are indexed under Rhabdomyosarcoma; 49 are open to participants now.

Browse Rhabdomyosarcoma studies →

Open to participants now

4 of the 32 studies in Rhabdomyosarcoma with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 39 Rhabdomyosarcoma studies recruiting now, 8 (21%) set no upper age limit and 31 (79%) stop at 75 or younger; 35 take children under 18; none take healthy volunteers.

This study: 6 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Rhabdomyosarcoma with a site in Canada, or all of them as a file.
02

Study summary

This study will test the feasibility of using novel/existing imaging technologies focused on hypoxia measurements to determine "response to therapy" in pediatric soft tissue sarcomas as a pilot study. Specifically, the investigators will compare the sensitivity of Blood Oxygen Level Dependent [BOLD], Diffusion-Weighted [DW] MRI and Magnetic Resonance Spectroscopy (MRS) with that of conventional MRI to detect measurement changes between the start and completion of neoadjuvant therapy ("response to therapy") in children and adolescents (6-18 years) with suspicion of sarcoma tumors. Clinicians and scientists may use results of the proposed hypoxia-imaging surrogate markers to adjust/modify therapeutic schemes to patients on a personalized basis.

03

Conditions studied

  • Rhabdomyosarcoma
  • Non-Rhabdo. Soft Tissue Sarcoma
04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Referred with a confirmed or suspected sarcoma tumor (rhabdomyosarcoma [RMS] or non-rhabdomyomatous sarcoma) presenting with an extra-osseous component;
  • Candidate for therapy that will consist of standard systemic chemotherapy with or without radiation therapy

Exclusion criteria

Exclusion Criteria:

  • Patients with general for an MRI scan (metal foreign body, pacemaker, inability to tolerate an examination without sedation);
  • Patients with a known immunodeficiency/sickle cell disease/collagen vascular disease/another ;
  • Patients with no clinical indication for therapy prior to surgery;
  • Patients with chronic pulmonary disease;
  • Patients with other diagnosis confirmed after initial suspicion of RMS or non-RMS.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    BOLD- DW- MRS

    Blood Oxygen Level Dependent \[BOLD\], Diffusion-Weighted \[DW\] MRI, MR Spectroscopy \[MRS\]

    Diagnostic Test: Blood Oxygen Level Dependent [BOLD] MRI · Diagnostic Test: Diffusion-Weighted [DW] MRI · Diagnostic Test: Magnetic Resonance Spectroscopy [MRS]

Interventions

  • Diagnostic testBlood Oxygen Level Dependent [BOLD] MRI

    BOLD is a non-invasive T2\*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.

  • Diagnostic testDiffusion-Weighted [DW] MRI

    DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells

  • Diagnostic testMagnetic Resonance Spectroscopy [MRS]

    MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue

06

What researchers measure

Primary outcomes

  1. Number of participants with response to therapy

    Response will be assessed by measurements of tumor volume, percentage of BOLD signal changes, percentage of tumor necrosis, apparent diffusion coefficient, concentration of high-energy and low-energy phosphates in tumor.

    Time frame: 1 year

Secondary outcomes

  1. Associations between post-neoadjuvant therapy imaging measurements and surgical / histochemical outcomes in the residual tumor.

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No IPD data will be shared with other researchers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2017 (actual). Primary completion is estimated for Dec 2026, 115 months after the start.

Of 38 phase 1 interventional studies under Rhabdomyosarcoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 134. This study's planned 115 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2017
First posted
Feb 16, 2017
StartActual
May 1, 2017
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03054792
Responsible party
Andrea Doria (Radiologist, Scientist, Research Director, The Hospital for Sick Children) — Principal investigator
First posted
Feb 16, 2017
Start date
May 1, 2017
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion